Abpro Holdings, Inc. operates as a capital pool company. The company is headquartered in New York City, New York and currently employs 6 full-time employees. The company went IPO on 2022-01-14. The firm is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema. These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. The company plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).
Follow-Up Questions
What is the price performance of ABP stock?
The current price of ABP is $0.2045, it has increased 2.29% in the last trading day.
What are the primary business themes or industries for ABPRO Holdings Inc?
ABPRO Holdings Inc belongs to Biotechnology industry and the sector is Health Care
What is ABPRO Holdings Inc market cap?
ABPRO Holdings Inc's current market cap is $16.4M
Is ABPRO Holdings Inc a buy, sell, or hold?
According to wall street analysts, 2 analysts have made analyst ratings for ABPRO Holdings Inc, including 1 strong buy, 3 buy, 1 hold, 0 sell, and 1 strong sell
